GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV

NCT07221214 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

HIV
Alcohol
Smoking Cigarette
Cardiovascular Disease Prevention

Interventions

DRUG: Semaglutide (Rybelsus®)
DRUG: Placebo

Sponsor

Vanderbilt University Medical Center

Collaborators

[object Object]
[object Object]
[object Object]